RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024
RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM). Other select data from research studies unveiled last week at the American Heart Association's International Stroke Conference (ISC) underscore and reinforce the pivotal role of the RapidAI platform in advancing stroke care.
Data Summaries from Key Studies:
Subgroup Analyses from the TIMELESS Trial, by Gregory Albers, M.D., presented and simultaneously published in the NEJM.
Detecting MeVOs and Collateral Assessment with Multimodality AI Approach, by Sowlat et. al.
National database demonstrates substantial delays between non-contrast CT and CT angiography in suspected stroke patients in 2023, by Christina Mijalski Sells, M.D., and, Pina Sanelli, M.D. MPH, FACR.
Three subacute or chronic subdural hematoma (SDH) studies, EMBOLISE, MAGIC-MT, and STEM, were also reported at ISC; all showed positive results demonstrating a reduction in recurrence of the subdural when embolization of the middle meningeal artery (MMA) was used in addition to surgery versus surgery alone. SDH is one of the most common neurosurgical diseases and affects 1-21 per 100,000 patients per year, and the rate of recurrence requiring treatment is 12-20%.1,2,3 Many SDH patients are lost to follow-up. Proper identification and tracking of SDH through technology such as Rapid SDH will be beneficial in identifying patients most suitable for MMA procedures.
"In the world of AI, clinical validation is paramount to instill confidence in clinician decision-making," said Karim Karti, CEO of RapidAI. "Securing another NEJM publication and sharing results from more than a dozen studies at ISC 2024 reaffirms our lasting and ongoing contribution to enhancing stroke care."
RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from 12 million scans in more than 2,200 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI - where AI meets patient care.
1 Subdural evacuating port system for chronic subdural hematoma: a systematic review and meta-analysis of clinical outcomes, Egyptian Journal of Neurosurgery volume 38, Article number: 76 (2023)